Department of Intensive Care, Erasme University Hospital, Université libre de Bruxelles, Brussels, Belgium.
Edwards Lifesciences, Irvine, CA.
Crit Care Med. 2018 Aug;46(8):1224-1229. doi: 10.1097/CCM.0000000000003157.
Tight glycemic control using intermittent blood glucose measurements is associated with a risk of hypoglycemia. Glucose concentrations can now be measured near continuously (every 5-15 min). We assessed the quality and safety of glycemic control guided by a near-continuous glucose monitoring system in ICU patients.
Prospective, cluster-randomized, crossover study.
Thirty-five-bed medico-surgical department of intensive care with four separate ICUs.
Adult patients admitted to the department and expected to stay for at least 3 days were considered for inclusion if they had persistent hyperglycemia (blood glucose > 150 mg/dL) up to 6 hours after admission and/or were receiving insulin therapy.
A peripheral venous catheter was inserted in all patients and connected to a continuous glucose monitoring sensor (GlucoClear; Edwards Lifesciences, Irvine, CA). The four ICUs were randomized in pairs in a crossover design to glycemic control using unblinded or blinded continuous glucose monitoring monitors. The insulin infusion rate was adjusted to keep blood glucose between 90 and 150 mg/dL using the blood glucose values displayed on the continuous glucose monitor (continuous glucose monitoring group-unblinded units) or according to intermittent blood glucose readings (intermittent glucose monitoring group-blinded units).
The quality and safety of glycemic control were assessed using the proportion of time in range, the frequency of blood glucose less than 70 mg/dL, and the time spent with blood glucose less than 70 mg/dL (TB70), using blood glucose values measured by the continuous glucose monitoring device. Seventy-seven patients were enrolled: 39 in the continuous glucose monitoring group and 38 in the intermittent glucose monitoring group. A total of 43,107 blood glucose values were recorded. The time in range was similar in the two groups. The incidence of hypoglycemia (8/39 [20.5%] vs 15/38 [39.5%]) and the TB70 (0.4% ± 0.9% vs 1.6% ± 3.4%; p < 0.05) was lower in the continuous glucose monitoring than in the intermittent glucose monitoring group.
Use of a continuous glucose monitoring-based strategy decreased the incidence and severity of hypoglycemia, thus improving the safety of glycemic control.
使用间歇性血糖测量进行严格的血糖控制与低血糖风险相关。现在可以近乎连续(每 5-15 分钟)测量血糖浓度。我们评估了 ICU 患者使用近连续血糖监测系统指导的血糖控制的质量和安全性。
前瞻性、集群随机、交叉研究。
35 张病床的内科-外科重症监护病房,有四个单独的 ICU。
如果患者在入院后 6 小时内持续高血糖(血糖>150mg/dL)和/或正在接受胰岛素治疗,则将其纳入符合条件的成年患者,并预计至少在该部门停留 3 天。
所有患者均插入外周静脉导管,并连接到连续血糖监测传感器(GlucoClear;爱德华生命科学公司,欧文,加利福尼亚州)。四个 ICU 以配对方式随机分为两组,使用未盲或盲目的连续血糖监测仪进行血糖控制。使用连续血糖监测仪上显示的血糖值(连续血糖监测组-未盲单位)或根据间歇性血糖读数(间歇性血糖监测组-盲单位)调整胰岛素输注率,以将血糖保持在 90 至 150mg/dL 之间。
使用连续血糖监测仪测量的血糖值评估血糖控制的质量和安全性,包括达标时间比例、血糖低于 70mg/dL 的频率以及血糖低于 70mg/dL 的时间(TB70)。77 名患者入组:连续血糖监测组 39 名,间歇性血糖监测组 38 名。共记录了 43107 个血糖值。两组的达标时间相似。连续血糖监测组低血糖发生率(8/39 [20.5%] vs 15/38 [39.5%])和 TB70(0.4%±0.9%vs 1.6%±3.4%;p<0.05)低于间歇性血糖监测组。
使用基于连续血糖监测的策略可降低低血糖的发生率和严重程度,从而提高血糖控制的安全性。